永泰生物-B(06978.HK)就北京建研发及产业化基地订建造协议 涉逾6.6亿人币
永泰生物-B(06978.HK)公布,公司透过其间接全资附属北京永泰与承建商中建三局订立建造协议,内容有关於中国北京兴建研发及产业化基地,合约金额为6.65亿元人民币。
中建三局将负责进行研发及产业化基地的建设及工程作业,该基地的总地盘面3.5万平方米,总施工面积为12.1万平方米。建造工程包括多幢用作质检、综合用途、细胞疗法及其他生产车间、仓库及雨水收集缸的建筑物。预计建造期由今年3月15日至2023年9月1日。(ek/a)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.